Literature DB >> 15806201

The epidemic of the metabolic syndrome.

Wael N Elabbassi1, Haissam A Haddad.   

Abstract

The incidence of metabolic syndrome (MS) is rising worldwide. This is partly due to a significant increase in the prevalence of obesity. Observational cross-sectional studies as well as demographic health surveys from the Middle East, point out that the prevalence of obesity increases from an average of 6% in healthy children to 20% in adolescent males and to a further 32% in elderly patients. The impact of obesity on our population is expected to be considerable; especially, as it feeds into further rising in the prevalence of hypertension, diabetes, MS and cardiovascular disease. The prevalence of MS in nondiabetic adults in Europe was recently reported to be 15%. In the Middle East, as pointed out by pilot observational projects, is estimated to be anywhere between 15-25%. The medical system is unprepared to deal with this epidemic partly due to scanty knowledge on the clinical significance of the MS and importantly as there is a limited number of specific treatments that we can offer these patients.

Entities:  

Mesh:

Year:  2005        PMID: 15806201

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  8 in total

1.  Empirical evidence for "syndrome Z": a hierarchical 5-factor model of the metabolic syndrome incorporating sleep disturbance measures.

Authors:  Nora L Nock; Li Li; Emma K Larkin; Sanjay R Patel; Susan Redline
Journal:  Sleep       Date:  2009-05       Impact factor: 5.849

Review 2.  Understanding the Role of Metabolic Syndrome as a Risk Factor for Hepatocellular Carcinoma.

Authors:  Norberto C Chavez-Tapia; Sofía Murúa-Beltrán Gall; Ana Luisa Ordoñez-Vázquez; Natalia Nuño-Lambarri; Paulina Vidal-Cevallos; Misael Uribe
Journal:  J Hepatocell Carcinoma       Date:  2022-07-05

3.  Glucose metabolism disorder in obese children assessed by continuous glucose monitoring system.

Authors:  Chao-Chun Zou; Li Liang; Fang Hong; Zheng-Yan Zhao
Journal:  World J Pediatr       Date:  2008-02       Impact factor: 2.764

4.  Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.

Authors:  Ghazi Ahmad Radaideh; Patrick Choueiry; Amr Ismail; Elie Eid; Jean-Pascal Berrou; Armand Sedefdjian; Frank Sévenier; Atul Pathak
Journal:  Vasc Health Risk Manag       Date:  2011-08-01

Review 5.  The Effect of Lifestyle Intervention on Health-Related Quality of Life in Adults with Metabolic Syndrome: A Meta-Analysis.

Authors:  Alba Marcos-Delgado; Natalia Hernández-Segura; Tania Fernández-Villa; Antonio J Molina; Vicente Martín
Journal:  Int J Environ Res Public Health       Date:  2021-01-20       Impact factor: 3.390

6.  Defining genetic determinants of the Metabolic Syndrome in the Framingham Heart Study using association and structural equation modeling methods.

Authors:  Nora L Nock; Xuefeng Wang; Cheryl L Thompson; Yeunjoo Song; Dan Baechle; Paola Raska; Catherine M Stein; Courtney Gray-McGuire
Journal:  BMC Proc       Date:  2009-12-15

Review 7.  Rationale for multiple risk intervention: the need to move from theory to practice.

Authors:  Leif R Erhardt
Journal:  Vasc Health Risk Manag       Date:  2007

8.  MicroRNA expression profile and identification of novel microRNA biomarkers for metabolic syndrome.

Authors:  Guanzhi Liu; Yutian Lei; Sen Luo; Zhuo Huang; Chen Chen; Kunzheng Wang; Pei Yang; Xin Huang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.